<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">J Proteome Res</journal-id>
    <journal-id journal-id-type="iso-abbrev">J Proteome Res</journal-id>
    <journal-id journal-id-type="publisher-id">pr</journal-id>
    <journal-id journal-id-type="coden">jprobs</journal-id>
    <journal-title-group>
      <journal-title>Journal of Proteome Research</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">1535-3893</issn>
    <issn pub-type="epub">1535-3907</issn>
    <publisher>
      <publisher-name>American Chemical
Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8041382</article-id>
    <article-id pub-id-type="pmid">33661646</article-id>
    <article-id pub-id-type="doi">10.1021/acs.jproteome.0c00902</article-id>
    <article-categories>
      <subj-group>
        <subject>Technical Note</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Triqler for MaxQuant: Enhancing Results from MaxQuant
by Bayesian Error Propagation and Integration</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="ath1">
        <name>
          <surname>The</surname>
          <given-names>Matthew</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes" id="ath2">
        <name>
          <surname>Käll</surname>
          <given-names>Lukas</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <aff id="aff1"><label>†</label>Chair
of Proteomics and Bioanalytics, <institution>Technische
Universität München</institution>, Emil-Erlenmeyer Forum 5, 85354 Freising, <country>Germany</country></aff>
      <aff id="aff2"><label>‡</label>Science
for Life Laboratory, School of Engineering Sciences in Chemistry,
Biotechnology and Health, <institution>Royal Institute
of Technology − KTH</institution>, Box 1031, 17121 Solna, <country>Sweden</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Email: <email>lukask@kth.se</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>04</day>
      <month>03</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="ppub">
      <day>02</day>
      <month>04</month>
      <year>2021</year>
    </pub-date>
    <volume>20</volume>
    <issue>4</issue>
    <issue-title>Software Tools and Resources 2021</issue-title>
    <fpage>2062</fpage>
    <lpage>2068</lpage>
    <history>
      <date date-type="received">
        <day>10</day>
        <month>11</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2021 The
Authors. Published by American
Chemical Society</copyright-statement>
      <copyright-year>2021</copyright-year>
      <copyright-holder>The Authors</copyright-holder>
      <license>
        <license-p>Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr0c00902_0005" id="ab-tgr1"/>
      </p>
      <p>Error estimation
for differential protein quantification by label-free
shotgun proteomics is challenging due to the multitude of error sources,
each contributing uncertainty to the final results. We have previously
designed a Bayesian model, Triqler, to combine such error terms into
one combined quantification error. Here we present an interface for
Triqler that takes MaxQuant results as input, allowing quick reanalysis
of already processed data. We demonstrate that Triqler outperforms
the original processing for a large set of both engineered and clinical/biological
relevant data sets. Triqler and its interface to MaxQuant are available
as a Python module under an Apache 2.0 license from <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pypi.org/project/triqler/">https://pypi.org/project/triqler/</uri>.</p>
    </abstract>
    <kwd-group>
      <kwd>mass spectrometry</kwd>
      <kwd>proteomics</kwd>
      <kwd>Bayesian
statistics</kwd>
      <kwd>quantification</kwd>
      <kwd>label-free quantification</kwd>
    </kwd-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>pr0c00902</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>pr0c00902</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <title>Introduction</title>
    <p>In
mass-spectrometry (MS)-based proteomics, label-free quantification
(LFQ) enables the study of relative concentrations of proteins in
complex mixtures. The technique scales easily to large sample cohorts
and can handle complex experimental designs.</p>
    <p>The data processing
of such samples contains a chain of processing
steps that depend on each other. Typically, MS1 features are extracted
for each MS run and are subsequently matched to peptide sequences
independently of the other runs. Optionally, the different MS runs
are aligned to each other, and missing peptide intensities are extracted
using so-called match-between-runs techniques.<sup><xref ref-type="bibr" rid="ref1">1</xref>,<xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref18">18</xref></sup> In each processing step, thresholds are
applied to the measurements based on quality metrics, either statistically
motivated or simply selected according to best practices; that is,
the data that are deemed reliable are shrinking in each processing
step.</p>
    <p>Strict partitioning is not just unnecessary, it is also
harmful
to the performance of LFQ experiments. We previously designed a Bayesian
method, Triqler, to integrate different error sources into combined
quantification posterior error probabilities, which we demonstrated
to dramatically improve both the precision and the recall of LFQ experiments.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> It also addressed the issue of missing values,
another major problem for LFQ data analysis,<sup><xref ref-type="bibr" rid="ref6">6</xref>,<xref ref-type="bibr" rid="ref15">15</xref></sup> by
using the Bayesian framework to appropriately assign probabilities
to a range of expression values. The advantages of Bayesian statistics
in protein quantification is by no means limited to LFQ processing.
More generally, it has been successfully applied to isobaric labeling
experiments<sup><xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref10">10</xref></sup> and for clustering quantification
data.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup></p>
    <p>Triqler’s lack of
support for match-between-runs was addressed
in a follow-up article.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> However, we are
aware that a complete reanalysis using a novel method is not always
practical. A very popular pipeline for processing LFQ data is the
MaxLFQ<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> software, which includes match-between-runs,
followed by postprocessing with the Perseus package.<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> We hence find it worthwhile to plug into this user base
and provide an alternative means to interpret the output from the
MaxLFQ pipeline. We specifically note the potential of the increasingly
more common practice of depositing results of processing analyses
to repositories, such as MassIVE<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> and PRIDE.<sup><xref ref-type="bibr" rid="ref9">9</xref></sup></p>
    <p>Both MaxLFQ and Perseus, to large extents,
follow the classical
threshold-based processing pipeline. Here we show how Triqler can
be used in the place of Perseus, which effectively converts the MaxLFQ
workflow into a Bayesian processing method. The input to Triqler will
in this case be the <monospace>evidence.txt</monospace> file directly
obtainable from MaxLFQ. The processing not only renders a dramatic
performance improvement but also gives a more detailed insight into
the reliability of each protein’s quantitative values using
Triqler’s new posterior distribution plotting capabilities.</p>
  </sec>
  <sec id="sec2">
    <title>Methods</title>
    <sec id="sec2.1">
      <title>Data Sets</title>
      <p>To examine the validity of the results, we
analyzed three engineered data sets, where known proteins were spiked
into a background at known concentrations. For this, we downloaded
MaxQuant result files for a study where UPS proteins were spiked in
at three concentrations in a yeast background, which we will refer
to as the UPS-Yeast set (PRIDE project: PXD002370, <monospace>Ratio2_txt.zip</monospace> and <monospace>Ratio2.5_txt.zip</monospace>). We also downloaded
MaxQuant <monospace>evidence.txt</monospace> files from MassIVE.quant
for a reanalysis of the iPRG2015 data set (RMSV000000248.33), in which
six proteins were spiked in at four different concentrations in a
yeast background, and the MaxLFQ benchmark data set (RMSV000000255.1),
with UPS1/UPS2 proteins spiked into an <italic>E. coli</italic> lysate.</p>
      <p>Furthermore, we downloaded the MaxQuant results uploaded to PRIDE
for four recent biological and clinical studies: (1) a study investigating
temozolomide resistance in glioblastoma<sup><xref ref-type="bibr" rid="ref17">17</xref></sup> (PXD007759), (2) a clinical study examining CD4+ and CD8+ T-cells
of multiple sclerosis patients<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> (PXD011785),
(3) a clinical data set investigating biomarkers for cholangiocarcinoma<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> (PXD011804), and (4) a proteogenomics study of
nonsmall and small lung carcinoma cell lines<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> (PXD015270). For the Glioblastoma data set, as was done in the original
study, we only analyzed the results of the samples in the T_ZHI sample
group, i.e., the samples treated with temozolomide together with dimethyl
sulfoxide, and D_ZHI sample group, i.e., the sample group with dimethyl
sulfoxide only, but still used the identifications transferred by
match-between-runs reported in the evidene.txt file.</p>
    </sec>
    <sec id="sec2.2">
      <title>Data Analysis</title>
      <p>MaxQuant <monospace>evidence.txt</monospace> files were converted
to Triqler input files using the <monospace>triqler.convert.maxquant</monospace> program from Triqler v0.6.1.
For this, we used the Andromeda scores reported by MaxQuant to compute
the Triqler peptide-spectrum match (PSM) score as log(<italic>score</italic>). We used the leading protein(s) as reported by MaxQuant as the
corresponding protein for a peptide. Feature intensities were normalized
using a retention-time-dependent normalization scheme.<sup><xref ref-type="bibr" rid="ref18">18</xref></sup> For the Glioblastoma data set, we used the <monospace>--use_gene_names</monospace> option to use gene names instead of
protein identifiers to allow better comparison with the results from
the original study.</p>
      <p>The converted input file was then processed
by Triqler v0.6.1 with default parameters, except for the minimum
number of present values per peptide <italic>S</italic> (<monospace>--min_samples</monospace>) and the log<sub>2</sub> fold-change threshold <italic>F</italic> (<monospace>--fold_change_eval</monospace>), which are
listed in <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref> and
were chosen based on comparable parameters used in the original studies.</p>
      <table-wrap id="tbl1" position="float">
        <label>Table 1</label>
        <caption>
          <title>Summary of Data Sets and Results<xref rid="tbl1-fn1" ref-type="table-fn">a</xref></title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="left"/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">data set</th>
              <th style="border:none;" align="center" char=".">samples</th>
              <th style="border:none;" align="center" char=".">groups</th>
              <th style="border:none;" align="center" char=".">
                <italic>S</italic>
              </th>
              <th style="border:none;" align="center" char=".">
                <italic>F</italic>
              </th>
              <th style="border:none;" align="center"><italic>DE</italic> proteins (5% FDR)</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="left">iPRG2015</td>
              <td style="border:none;" align="char" char=".">12</td>
              <td style="border:none;" align="char" char=".">4</td>
              <td style="border:none;" align="char" char=".">7</td>
              <td style="border:none;" align="char" char=".">0.5</td>
              <td style="border:none;" align="left">30 tp (max: 30) + 0 fp</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">MaxLFQ benchmark</td>
              <td style="border:none;" align="char" char=".">8</td>
              <td style="border:none;" align="char" char=".">2</td>
              <td style="border:none;" align="char" char=".">4</td>
              <td style="border:none;" align="char" char=".">1.0</td>
              <td style="border:none;" align="left">37 tp (max: 40) + 2 fp</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">UPS-Yeast Ratio2</td>
              <td style="border:none;" align="char" char=".">6</td>
              <td style="border:none;" align="char" char=".">2</td>
              <td style="border:none;" align="char" char=".">3</td>
              <td style="border:none;" align="char" char=".">0.8</td>
              <td style="border:none;" align="left">9 tp (max: 48) + 0 fp</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">UPS-Yeast Ratio2.5</td>
              <td style="border:none;" align="char" char=".">6</td>
              <td style="border:none;" align="char" char=".">2</td>
              <td style="border:none;" align="char" char=".">3</td>
              <td style="border:none;" align="char" char=".">0.8</td>
              <td style="border:none;" align="left">39 tp (max: 48) + 0 fp</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">Glioblastoma</td>
              <td style="border:none;" align="char" char=".">6</td>
              <td style="border:none;" align="char" char=".">2</td>
              <td style="border:none;" align="char" char=".">3</td>
              <td style="border:none;" align="char" char=".">1.0</td>
              <td style="border:none;" align="left">270</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">Multiple sclerosis</td>
              <td style="border:none;" align="char" char=".">27</td>
              <td style="border:none;" align="char" char=".">2</td>
              <td style="border:none;" align="char" char=".">17</td>
              <td style="border:none;" align="char" char=".">0.5</td>
              <td style="border:none;" align="left">10</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">Cholangiocarcinoma</td>
              <td style="border:none;" align="char" char=".">30</td>
              <td style="border:none;" align="char" char=".">3</td>
              <td style="border:none;" align="char" char=".">8</td>
              <td style="border:none;" align="char" char=".">0.5</td>
              <td style="border:none;" align="left">50</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">Lung cancer</td>
              <td style="border:none;" align="char" char=".">12</td>
              <td style="border:none;" align="char" char=".">2</td>
              <td style="border:none;" align="char" char=".">6</td>
              <td style="border:none;" align="char" char=".">1.0</td>
              <td style="border:none;" align="left">278</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="tbl1-fn1">
            <label>a</label>
            <p>Results for the engineered data
sets (iPRG2015, MaxLFQ benchmark, UPS-Yeast Ratio2, and UPS-Yeast
Ratio2.5) demonstrate the high sensitivity and correct FDR control
of Triqler. For each of the biological data sets (Glioblastoma, Multiple
sclerosis, Cholangiocarcinoma, and Lung cancer), Triqler finds differentially
abundant proteins after multiple testing corrections, which the original
studies generally were unable to do. <italic>S</italic> is the minimum
number of nonmissing values for a peptide to be retained. <italic>F</italic> is the log<sub>2</sub> fold-change threshold used to evaluate
the differential abundance. <italic>DE</italic> proteins is the number
of differentially abundant proteins at 5% differential abundance FDR.
If more than two groups were present, then this column lists the sum
of the differentially abundant proteins for each pairwise comparison.
For the engineered data sets, the first number is the number of true-positives
(tp), with the maximum number of true-positives given in parentheses,
and the last number is the number of false-positives (fp).</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="sec2.3">
      <title>Limitations and Requirements</title>
      <p>The
data sets presented
here used the default MaxLFQ false discovery rate (FDR) threshold
of 1%; however, when processing new data sets, we recommend that the
FDR thresholds are changed to 100% FDR before starting the MaxQuant
processing. This assures that all peptide quantification values are
properly transferred to Triqler. Also, although all data sets made
use MaxLFQ’s match-between-runs feature, the current converter
does not take into account errors from this process.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> A better alternative to this is presented by our method,
Quandenser,<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> which evaluates the uncertainty
in the feature alignments and thereby increases the precision in the
processing even further.</p>
      <p>An assumption in the Triqler model
is that the majority of the proteins will not change between conditions.
However, even if this assumption is violated, we have previously obtained
reasonable results.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> Furthermore, care
should be taken in specifying the maximum allowed number of missing
values per peptide. The more missing values are allowed, the less
reliable the estimation of the missing value distribution becomes.
However, we have observed that Triqler can obtain reasonable error
estimates when allowing up to 70% of the runs to have missing values
for a peptide.<sup><xref ref-type="bibr" rid="ref13">13</xref></sup></p>
      <p>A typical run of
Triqler takes under 5 min and requires &lt;1 GB
of RAM. Thus far, we have not observed a case in which Triqler was
unable to handle a data set due to too large of a number of PSMs,
peptides, or proteins. The largest data set analyzed by Triqler to
date had 500 000 PSMs, 60 000 peptides, and 6000 proteins
and finished in 10 min using four cores and 4.5 GB of RAM.</p>
    </sec>
  </sec>
  <sec id="sec3">
    <title>Results
and Discussion</title>
    <p>We implemented an interface from MaxQuant
to Triqler. The interface
had only one input, converting MaxQuant <monospace>evidence.txt</monospace> to Triqler input files, and required no intervention in the setup
of the MaxLFQ processing. We benchmarked the performance of the combination
of MaxLFQ and Triqler on all data sets. An overview of the results
is given in <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>, and we will walk through the results for each data set in the sections
below.</p>
    <sec id="sec3.1">
      <title>Engineered Data Sets</title>
      <p>First, we characterized the behavior
of our new MaxLFQ+Triqler pipeline on three engineered data sets,
starting with the UPS-Yeast data set. Employing the fold-change evaluation
threshold of 0.8, as in the original Triqler article, we found a comparable
performance to the original Triqler pipeline with 39 true-positives
and 0 false-positives for the Ratio2.5 set (<xref rid="fig1" ref-type="fig">Figures <xref rid="fig1" ref-type="fig">1</xref></xref>A,B and <xref rid="fig2" ref-type="fig">2</xref>); however,
we noted a rather low sensitivity for the Ratio2 set, with only 9
true-positives and 0 false-positives. This seemed to be due to an
underestimation of the fold change for the UPS proteins, which Triqler
estimated to be closer to the evaluation threshold of 0.8 than to
the spike-in ratio of 1.0 (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>C). Lowering the fold-change evaluation threshold to
0.5 appreciably increased the sensitivity to 44 and 28 true-positives
for the Ratio2.5 and Ratio2 sets, respectively, while retaining specificity,
with 0 false-positives in both cases.</p>
      <fig id="fig1" position="float">
        <label>Figure 1</label>
        <caption>
          <p>Posterior fold-change distributions allow
for a quick and intuitive
interpretation of Triqler’s results. (a) Posterior distributions
of the log<sub>2</sub> fold change for the spiked-in UPS proteins
in the UPS-Yeast Ratio2.5 data set correctly center around log<sub>2</sub>(2.5) = 1.3. The proteins are sorted by the confidence of
the protein identification, with high-confidence proteins (multiple
high-confidence peptides) at the top and low-confidence proteins (few
or low-confidence peptides) at the bottom. (b) The number of true-positive
differentially abundant proteins in the UPS-Yeast Ratio2.5 data set
slowly decreases as a function of an increasing fold-change evaluation
threshold. The lower bound for this threshold is given in orange and
is calculated from the standard deviation of the protein prior distribution.
Below this lower bound, the number of false-positives rapidly increases.
(c) For the UPS-Yeast Ratio2 set, the initially chosen threshold of
0.8 leads to very low sensitivity. On the basis of the lower bound
estimation, a threshold of 0.5 is still within the range where few
false-positives will occur.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr0c00902_0001" id="gr1" position="float"/>
      </fig>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Posterior
distributions reflect the uncertainty of the input data.
Posterior distributions for three UPS proteins at the protein, the
treatment group, and the fold change between group levels for the
UPS-Yeast Ratio2.5 data set. The plots exemplify the different degrees
of confidence in the differential abundance, as inferred by Triqler.
For P02788, we have multiple peptide identifications that all agree
on the relative abundances, which leads to a narrow posterior distribution.
For O00762 and Q15483, fewer peptides were identified, and some missing
values were present, which leads to wider posterior distributions
and, in the case of Q15483, a visible influence of the protein prior
to “pulling” the distribution toward 0.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr0c00902_0002" id="gr2" position="float"/>
      </fig>
      <p>More generally, the fold-change evaluation threshold should
be
chosen based on the biological question. In practice, many differential
expression analyses already use this type of fold-change threshold
to filter out low effect sizes. However, there are some differences
between this fold-change threshold and our Bayesian fold-change evaluation
threshold. First, the Bayesian threshold should be higher than two
tot three standard deviations of the fold-change distribution that
results from the prior distributions (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.0c00902/suppl_file/pr0c00902_si_001.pdf">Supporting Information</ext-link>). Triqler calculates this value from the hyperparameter
estimations, prints it in the logs, and warns the user if the chosen
threshold is below this value. In practice, this typically leads to
a lower bound for the log<sub>2</sub> fold change of ∼0.5.
Below this lower bound, we expect an accumulation of false-positives
due to technical or biological variation (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>B,C, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.0c00902/suppl_file/pr0c00902_si_001.pdf">Figure S1</ext-link>). Second, for the traditional fold-change cutoff, only the fold
change of the group means needs to exceed the chosen value. In Triqler’s
case, the bulk of the posterior’s probability mass, for example,
95% to obtain a posterior error probability of 0.05, needs to exceed
the chosen value, which is a much more strict requirement. This effect
can be seen in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>.</p>
      <fig id="fig3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Genes and proteins close to a fold-change threshold risk being
overlooked. (a) Gene RPL21 was called differentially expressed in
the original study of the Glioblastoma data set but missed the 5%
FDR cutoff in the Triqler analysis because the log<sub>2</sub> fold
change was close to 1.0. (b) Gene RPL13 was not called differentially
abundant in the original study or by Triqler; however, it shows equally
strong evidence of differential expression as RPL21 and should ideally
be taken into account as evidence of the regulation of the Ribosome
KEGG pathway in downstream pathway analysis tools.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr0c00902_0003" id="gr3" position="float"/>
      </fig>
      <p>Next, we analyzed the iPRG2015 data set with Triqler using
the
MaxQuant results from a reanalysis by MaxQuant with match-between-runs
uploaded to MassIVE. Our new pipeline resulted in perfect recall and
precision at 5% FDR, that is, neither false-positives nor false-negatives.
We analyzed this same set as that in The and Käll<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> with several pipelines without match-between-runs.
In that benchmark, the MaxQuant+Perseus pipeline displayed a very
low sensitivity, frequently only calling one of the six spike-in proteins
as differentially expressed. Furthermore, it showed problems with
specificity as well, producing a couple of false-positives. On the
contrary, a pipeline using Triqler without MaxQuant identified the
spiked-in proteins without any false-positives or false-negatives
as well.</p>
      <p>Finally, we looked at a MaxQuant reanalysis of the
MaxLFQ benchmark
data set uploaded to MassIVE. We found 37 out of the 40 differentially
abundant UPS proteins at 5% FDR. We also found two of the eight nondifferentially
abundant UPS proteins making the 5% FDR cutoff as well, although they
were both very close to the FDR threshold.</p>
    </sec>
    <sec id="sec3.2">
      <title>Biological and Clinical
Data Sets</title>
      <p>In the original study
of the Glioblastoma data set, the authors found 65 up- and 96 down-regulated
genes significantly differentially expressed based on a <italic>t</italic> test and filtering for uncorrected <italic>p</italic> values below
0.05. Unfortunately, the submitted data were not detailed enough to
allow the application of multiple testing correction. Triqler found
106 up- and 164 down-regulated genes at 5% FDR. The overlap was 55
genes (25 up- and 30 down-regulated genes). Triqler did not call a
large part of the genes found in the original study differentially
expressed due to two reasons. First, about half of these genes have
only one or two peptides, the evidence of which was not strong enough
to overcome the prior (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.0c00902/suppl_file/pr0c00902_si_001.pdf">Figure S2</ext-link>). Second,
genes with a log<sub>2</sub> fold changes close to 1.0 will result
in posterior fold-change distributions with approximately equal probabilities
on both sides of this cutoff (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>a). This highlights the limitations of setting thresholds
before the pathway analysis.</p>
      <p>Looking at the most confidently
up- and down-regulated KEGG pathways reported in the original study
again underlines the issue of using hard partitioning by using a threshold
(<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig">4</xref></xref>). For the
Ribosome pathway (ko03010), many genes show expression values close
to a log<sub>2</sub> fold change of 1.0, for example, RPL13 (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>b). This gene was
not reported as differentially expressed in the original study but
does show a clear down-regulation in the posterior distribution plot.
Triqler allows the user to easily create these heatmap posterior plots
based on a list of genes or proteins to get a more thorough image
of the pathway expression.</p>
      <fig id="fig4" position="float">
        <label>Figure 4</label>
        <caption>
          <p>Pathways can be easily inspected by heatmaps
of posterior distributions.
Heatmap of posterior distributions of the fold change for the (a)
Ribosome KEGG pathway (ko03010) and (b) Regulation of actin cytoskeleton
KEGG pathway (ko04810) of the Glioblastoma data set. The genes are
sorted by confidence of the gene being identified, with genes with
multiple high-confidence peptides closer to the top and genes with
few or low-confidence peptides toward the bottom. The ko03010 pathway
shows very consistent down-regulation, whereas the ko04810 pathway
displays both up- and down-regulated genes.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr0c00902_0004" id="gr4" position="float"/>
      </fig>
      <p>Second, we reprocessed the Multiple sclerosis data set. The original
study<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> reported 228 and 195 differentially
abundant proteins for the CD4+ and CD8+ T cells, respectively, using
a <italic>p</italic> &lt; 0.05 criterion. After we applied the Benjamini–Hochberg
correction for multiple testing, none of these proteins remained significant
at 5% differential-abundance FDR. Applying Triqler to MaxQuant’s
evidence file resulted in 10 differentially abundant proteins at 5%
differential abundance FDR for the CD4+ T cells, with 5 overlapping
with the original list of 228 proteins at <italic>p</italic> &lt;
0.05. Most of the proteins called significant at <italic>p</italic> &lt; 0.05 in the original study were not called by Triqler because
they were artifacts of the multiple testing problem or were due to
low effect size (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.0c00902/suppl_file/pr0c00902_si_001.pdf">Figure S3</ext-link>). For the CD8+
T cells, no differentially abundant proteins were found with Triqler
at 5% differential abundance FDR, but five proteins were found at
10% differential abundance FDR. None of these appeared in the <italic>p</italic>-value-filtered list of the original study. This appears
to have been a result of one of the control samples clustering with
the Multiple sclerosis samples, as was also observed in the original
study. Triqler’s Bayesian model assigns less importance to
such outliers compared with a <italic>t</italic> test.</p>
      <p>Next,
we investigated the Cholangiocarcinoma data set. Here he
original study used a pipeline of MaxLFQ followed by the mixOmics
R package.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> This resulted in zero, two,
and three differentially abundant proteins at 5% differential abundance
FDR for the premalignant periductal fibrosis (PDF)–Normal,
Cholangiocarcinoma (CCA)–Normal, and CCA–PDF comparisons,
respectively. Reanalysis with Triqler resulted in 1, 19, and 30 differentially
expressed proteins for these respective comparisons at the same FDR
threshold. The sets found by Triqler included the differentially abundant
proteins from the original study at 5% FDR, except for Q96PD5, and
showed a large overlap with the list of differentially abundant proteins
with uncorrected <italic>p</italic> values below 0.05 in the original
study (2, 29, and 30 proteins, respectively).</p>
      <p>Finally, we reanalyzed
the Lung cancer data set. In the original
study,<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> the authors found 147 differentially
abundant proteins using |log<sub>2</sub><italic>FC</italic>| &gt;
1.0
as the criterion without applying any statistical tests. Reanalysis
with Triqler resulted in 278 differentially abundant proteins at 5%
differential abundance FDR with an overlap of 88 proteins with the
list of differentially abundant proteins from the original study.
Out of the 14 differentially abundant proteins that had a Pearson
correlation &gt;0.4 with microarray mRNA expression levels in the
original
study, 11 were also called differentially abundant by Triqler.</p>
    </sec>
  </sec>
  <sec id="sec4">
    <title>Conclusions</title>
    <p>Here we have shown that with very little effort, users can extract
new information from previously processed data from MaxQuant using
our Triqler interface. There is often a sizable overlap with the differentially
abundant proteins at <italic>p</italic>-value thresholds, but Triqler
is able to eliminate false-positives caused by multiple testing, unreliable
data, incoherent data, and poor missing value imputation. Also, instead
of reporting three separate values for the identification probability,
fold change, and significance value for differential expression for
each protein, Triqler reports a posterior fold-change distribution
that is intuitive to interpret and incorporates all three pieces of
information.</p>
    <p>Bayesian statistics is also helpful for downstream
analysis. Whereas
we here described how to generate statistics for lists of differentially
abundant proteins, this is seldom the end goal of an experiment. Often,
we strive to examine higher level questions, such as is a particular
metabolic pathway differentially regulated, or are the proteins from
a certain organelle differentially regulated? When using frequentist
tests, we would, in such situations, again partition our findings
based on an arbitrary selected FDR threshold; however, at least in
theory, this is better done by Bayesian models, allowing uncertainties
to propagate to the final question we want to answer.</p>
  </sec>
</body>
<back>
  <notes id="notes1" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting Information
is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acs.jproteome.0c00902?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jproteome.0c00902</ext-link>.<list id="silist" list-type="simple"><list-item><p>Note S1: Influence
of the fold-change evaluation threshold.
Figure S1: Lower bound estimate for the fold-change evaluation threshold
controls the number of false-positives. Table S1: UPS-Yeast Ratio2.5:
Number of false-positive and -negative quantifications for different
fold-change boundaries. Table S2: UPS-Yeast Ratio2: Number of false
-positive and -negative quantifications for different fold-change
boundaries. Table S3: MaxLFQ benchmark: Number of true-positive and
false-positive and -negative quantifications for different fold-change
boundaries. Table S4: iPRG2015: Number of true- and false-positive
quantifications for different fold-change boundaries. Table S5: Glioblastoma:
Number of significant differential abundant genes for different fold-change
boundaries. Table S6: Multiple sclerosis CD4: Number of significant
differential abundant proteins for different fold-change boundaries.
Table S7: Multiple sclerosis CD8: Number of significant differential
abundant proteins for different fold-change boundaries. Table S8:
Cholangiocarcinoma: Number of significant differential abundant proteins
for different fold-change boundaries. Table S9: Lung cancer: Number
of significant differential abundant proteins for different fold-change
boundaries. Figure S2: Posterior distributions of the fold-change
difference for up- and down-regulated genes according to the original
study of the Glioblastoma data set. Figure S3: Posterior distributions
of the fold-change difference for up- and down-regulated genes according
to the original study of the CD4+ and CD8+ data sets (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acs.jproteome.0c00902/suppl_file/pr0c00902_si_001.pdf">PDF</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pr0c00902_si_001.pdf">
        <caption>
          <p>pr0c00902_si_001.pdf</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="COI-statement" id="NOTES-d7e655-autogenerated">
    <p>The authors
declare no
competing financial interest.</p>
  </notes>
  <notes notes-type="" id="notes-999">
    <title>Notes</title>
    <p>Triqler and its interface to MaxQuant are
available as a Python module under an Apache 2.0 license from <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pypi.org/project/triqler/">https://pypi.org/project/triqler/</uri>.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>L.K. was supported by grants from the Swedish
Research
Council (grant 2017-04030) and Region Stockholm (grant 20191011).</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Argentini</surname><given-names>A.</given-names></name>; <name><surname>Goeminne</surname><given-names>L. J. E.</given-names></name>; <name><surname>Verheggen</surname><given-names>K.</given-names></name>; <name><surname>Hulstaert</surname><given-names>N.</given-names></name>; <name><surname>Staes</surname><given-names>A.</given-names></name>; <name><surname>Clement</surname><given-names>L.</given-names></name>; <name><surname>Martens</surname><given-names>L.</given-names></name><article-title>moFF: a robust
and
automated approach to extract peptide ion intensities</article-title>. <source>Nat. Methods</source><year>2016</year>, <volume>13</volume> (<issue>12</issue>), <fpage>964</fpage>–<lpage>966</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.4075</pub-id>.<pub-id pub-id-type="pmid">27898063</pub-id></mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Berge</surname><given-names>T.</given-names></name>; <name><surname>Eriksson</surname><given-names>A.</given-names></name>; <name><surname>Brorson</surname><given-names>I. S.</given-names></name>; <name><surname>Høgestøl</surname><given-names>E. A.</given-names></name>; <name><surname>Berg-Hansen</surname><given-names>P.</given-names></name>; <name><surname>Døskeland</surname><given-names>A.</given-names></name>; <name><surname>Mjaavatten</surname><given-names>O.</given-names></name>; <name><surname>Bos</surname><given-names>S. D.</given-names></name>; <name><surname>Harbo</surname><given-names>H. F.</given-names></name>; <name><surname>Berven</surname><given-names>F.</given-names></name><article-title>Quantitative proteomic
analyses of cd4+ and cd8+ t cells reveal differentially expressed
proteins in multiple sclerosis patients and healthy controls</article-title>. <source>Clin. Proteomics</source><year>2019</year>, <volume>16</volume> (<issue>1</issue>), <fpage>19</fpage><pub-id pub-id-type="doi">10.1186/s12014-019-9241-5</pub-id>.<pub-id pub-id-type="pmid">31080378</pub-id></mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Choi</surname><given-names>M.</given-names></name>; <name><surname>Carver</surname><given-names>J.</given-names></name>; <name><surname>Chiva</surname><given-names>C.</given-names></name>; <name><surname>Tzouros</surname><given-names>M.</given-names></name>; <name><surname>Huang</surname><given-names>T.</given-names></name>; <name><surname>Tsai</surname><given-names>T.-H.</given-names></name>; <name><surname>Pullman</surname><given-names>B.</given-names></name>; <name><surname>Bernhardt</surname><given-names>O. M.</given-names></name>; <name><surname>Huttenhain</surname><given-names>R.</given-names></name>; <name><surname>Teo</surname><given-names>G. C.</given-names></name>; <name><surname>Perez-Riverol</surname><given-names>Y.</given-names></name>; <name><surname>Muntel</surname><given-names>J.</given-names></name>; <name><surname>Muller</surname><given-names>M.</given-names></name>; <name><surname>Goetze</surname><given-names>S.</given-names></name>; <name><surname>Pavlou</surname><given-names>M.</given-names></name>; <name><surname>Verschueren</surname><given-names>E.</given-names></name>; <name><surname>Wollscheid</surname><given-names>B.</given-names></name>; <name><surname>Nesvizhskii</surname><given-names>A. I.</given-names></name>; <name><surname>Reiter</surname><given-names>L.</given-names></name>; <name><surname>Dunkley</surname><given-names>T.</given-names></name>; <name><surname>Sabido</surname><given-names>E.</given-names></name>; <name><surname>Bandeira</surname><given-names>N.</given-names></name>; <name><surname>Vitek</surname><given-names>O.</given-names></name><article-title>MassIVE.quant: a community resource of quantitative mass spectrometry–based
proteomics datasets</article-title>. <source>Nat. Methods</source><year>2020</year>, <volume>17</volume> (<issue>10</issue>), <fpage>981</fpage>–<lpage>984</lpage>. <pub-id pub-id-type="doi">10.1038/s41592-020-0955-0</pub-id>.<pub-id pub-id-type="pmid">32929271</pub-id></mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>Cox</surname><given-names>J.</given-names></name>; <name><surname>Hein</surname><given-names>M. Y.</given-names></name>; <name><surname>Luber</surname><given-names>C. A.</given-names></name>; <name><surname>Paron</surname><given-names>I.</given-names></name>; <name><surname>Nagaraj</surname><given-names>N.</given-names></name>; <name><surname>Mann</surname><given-names>M.</given-names></name><article-title>Accurate proteome-wide
label-free quantification by delayed normalization
and maximal peptide ratio extraction, termed MaxLFQ</article-title>. <source>Molecular &amp; Cellular Proteomics</source><year>2014</year>, <volume>13</volume> (<issue>9</issue>), <fpage>2513</fpage>–<lpage>2526</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.M113.031591</pub-id>.<pub-id pub-id-type="pmid">24942700</pub-id></mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Duangkumpha</surname><given-names>K.</given-names></name>; <name><surname>Stoll</surname><given-names>T.</given-names></name>; <name><surname>Phetcharaburanin</surname><given-names>J.</given-names></name>; <name><surname>Yongvanit</surname><given-names>P.</given-names></name>; <name><surname>Thanan</surname><given-names>R.</given-names></name>; <name><surname>Techasen</surname><given-names>A.</given-names></name>; <name><surname>Namwat</surname><given-names>N.</given-names></name>; <name><surname>Khuntikeo</surname><given-names>N.</given-names></name>; <name><surname>Chamadol</surname><given-names>N.</given-names></name>; <name><surname>Roytrakul</surname><given-names>S.</given-names></name>; <name><surname>Mulvenna</surname><given-names>J.</given-names></name>; <name><surname>Mohamed</surname><given-names>A.</given-names></name>; <name><surname>Shah</surname><given-names>A. K.</given-names></name>; <name><surname>Hill</surname><given-names>M. M.</given-names></name>; <name><surname>Loilome</surname><given-names>W.</given-names></name><article-title>Discovery and qualification
of serum protein biomarker candidates for cholangiocarcinoma diagnosis</article-title>. <source>J. Proteome Res.</source><year>2019</year>, <volume>18</volume> (<issue>9</issue>), <fpage>3305</fpage>–<lpage>3316</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.9b00242</pub-id>.<pub-id pub-id-type="pmid">31310545</pub-id></mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Lazar</surname><given-names>C.</given-names></name>; <name><surname>Gatto</surname><given-names>L.</given-names></name>; <name><surname>Ferro</surname><given-names>M.</given-names></name>; <name><surname>Bruley</surname><given-names>C.</given-names></name>; <name><surname>Burger</surname><given-names>T.</given-names></name><article-title>Accounting
for the multiple natures of missing values in label-free quantitative
proteomics data sets to compare imputation strategies</article-title>. <source>J. Proteome Res.</source><year>2016</year>, <volume>15</volume> (<issue>4</issue>), <fpage>1116</fpage>–<lpage>1125</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.5b00981</pub-id>.<pub-id pub-id-type="pmid">26906401</pub-id></mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Lim</surname><given-names>M. Y.</given-names></name>; <name><surname>Paulo</surname><given-names>J. A.</given-names></name>; <name><surname>Gygi</surname><given-names>S. P.</given-names></name><article-title>Evaluating
false transfer rates from
the match-between-runs algorithm with a two-proteome model</article-title>. <source>J. Proteome Res.</source><year>2019</year>, <volume>18</volume> (<issue>11</issue>), <fpage>4020</fpage>–<lpage>4026</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.9b00492</pub-id>.<pub-id pub-id-type="pmid">31547658</pub-id></mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>O’Brien</surname><given-names>J. J.</given-names></name>; <name><surname>O’Connell</surname><given-names>J. D.</given-names></name>; <name><surname>Paulo</surname><given-names>J. A.</given-names></name>; <name><surname>Thakurta</surname><given-names>S.</given-names></name>; <name><surname>Rose</surname><given-names>C. M.</given-names></name>; <name><surname>Weekes</surname><given-names>M. P.</given-names></name>; <name><surname>Huttlin</surname><given-names>E. L.</given-names></name>; <name><surname>Gygi</surname><given-names>S. P.</given-names></name><article-title>Compositional proteomics:
Effects of spatial constraints on protein quantification utilizing
isobaric tags</article-title>. <source>J. Proteome Res.</source><year>2018</year>, <volume>17</volume> (<issue>1</issue>), <fpage>590</fpage>–<lpage>599</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jproteome.7b00699</pub-id>.<pub-id pub-id-type="pmid">29195270</pub-id></mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Perez-Riverol</surname><given-names>Y.</given-names></name>; <name><surname>Csordas</surname><given-names>A.</given-names></name>; <name><surname>Bai</surname><given-names>J.</given-names></name>; <name><surname>Bernal-Llinares</surname><given-names>M.</given-names></name>; <name><surname>Hewapathirana</surname><given-names>S.</given-names></name>; <name><surname>Kundu</surname><given-names>D. J</given-names></name>; <name><surname>Inuganti</surname><given-names>A.</given-names></name>; <name><surname>Griss</surname><given-names>J.</given-names></name>; <name><surname>Mayer</surname><given-names>G.</given-names></name>; <name><surname>Eisenacher</surname><given-names>M.</given-names></name>; <name><surname>Perez</surname><given-names>E.</given-names></name>; <name><surname>Uszkoreit</surname><given-names>J.</given-names></name>; <name><surname>Pfeuffer</surname><given-names>J.</given-names></name>; <name><surname>Sachsenberg</surname><given-names>T.</given-names></name>; <name><surname>Yılmaz</surname><given-names>S.</given-names></name>; <name><surname>Tiwary</surname><given-names>S.</given-names></name>; <name><surname>Cox</surname><given-names>J.</given-names></name>; <name><surname>Audain</surname><given-names>E.</given-names></name>; <name><surname>Walzer</surname><given-names>M.</given-names></name>; <name><surname>Jarnuczak</surname><given-names>A. F</given-names></name>; <name><surname>Ternent</surname><given-names>T.</given-names></name>; <name><surname>Brazma</surname><given-names>A.</given-names></name>; <name><surname>Vizcaino</surname><given-names>J. A.</given-names></name><article-title>The pride
database and related tools and resources in 2019: improving support
for quantification data</article-title>. <source>Nucleic Acids Res.</source><year>2019</year>, <volume>47</volume> (<issue>D1</issue>), <fpage>D442</fpage>–<lpage>D450</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1106</pub-id>.<pub-id pub-id-type="pmid">30395289</pub-id></mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Peshkin</surname><given-names>L.</given-names></name>; <name><surname>Gupta</surname><given-names>M.</given-names></name>; <name><surname>Ryazanova</surname><given-names>L.</given-names></name>; <name><surname>Wuhr</surname><given-names>M.</given-names></name><article-title>Bayesian confidence
intervals for multiplexed proteomics integrate ion-statistics with
peptide quantification concordance</article-title>. <source>Molecular
&amp; Cellular Proteomics</source><year>2019</year>, <volume>18</volume> (<issue>10</issue>), <fpage>2108</fpage>–<lpage>2120</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.TIR119.001317</pub-id>.<pub-id pub-id-type="pmid">31311848</pub-id></mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="journal" id="cit11"><name><surname>Rohart</surname><given-names>F.</given-names></name>; <name><surname>Gautier</surname><given-names>B.</given-names></name>; <name><surname>Singh</surname><given-names>A.</given-names></name>; <name><surname>Lê Cao</surname><given-names>K.-A.</given-names></name><article-title>mixOmics:
An R package for ‘omics feature selection and multiple data
integration</article-title>. <source>PLoS Comput. Biol.</source><year>2017</year>, <volume>13</volume> (<issue>11</issue>), <elocation-id>e1005752</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1005752</pub-id>.<pub-id pub-id-type="pmid">29099853</pub-id></mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>The</surname><given-names>M.</given-names></name>; <name><surname>Käll</surname><given-names>L.</given-names></name><article-title>Integrated
identification and quantification error
probabilities for shotgun proteomics</article-title>. <source>Molecular
&amp; Cellular Proteomics</source><year>2019</year>, <volume>18</volume> (<issue>3</issue>), <fpage>561</fpage>–<lpage>570</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.RA118.001018</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>The</surname><given-names>M.</given-names></name>; <name><surname>Käll</surname><given-names>L.</given-names></name><article-title>Focus on the
spectra that matter by clustering of quantification
data in shotgun proteomics</article-title>. <source>Nat. Commun.</source><year>2020</year>, <volume>11</volume> (<issue>1</issue>), <fpage>3234</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-17037-3</pub-id>.<pub-id pub-id-type="pmid">32591519</pub-id></mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="journal" id="cit14"><name><surname>Tyanova</surname><given-names>S.</given-names></name>; <name><surname>Temu</surname><given-names>T.</given-names></name>; <name><surname>Sinitcyn</surname><given-names>P.</given-names></name>; <name><surname>Carlson</surname><given-names>A.</given-names></name>; <name><surname>Hein</surname><given-names>M. Y</given-names></name>; <name><surname>Geiger</surname><given-names>T.</given-names></name>; <name><surname>Mann</surname><given-names>M.</given-names></name>; <name><surname>Cox</surname><given-names>J.</given-names></name><article-title>The Perseus computational
platform for comprehensive analysis of (prote) omics data</article-title>. <source>Nat. Methods</source><year>2016</year>, <volume>13</volume> (<issue>9</issue>), <fpage>731</fpage><pub-id pub-id-type="doi">10.1038/nmeth.3901</pub-id>.<pub-id pub-id-type="pmid">27348712</pub-id></mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Webb-Robertson</surname><given-names>B.-J. M.</given-names></name>; <name><surname>Wiberg</surname><given-names>H. K.</given-names></name>; <name><surname>Matzke</surname><given-names>M. M.</given-names></name>; <name><surname>Brown</surname><given-names>J. N.</given-names></name>; <name><surname>Wang</surname><given-names>J.</given-names></name>; <name><surname>McDermott</surname><given-names>J. E.</given-names></name>; <name><surname>Smith</surname><given-names>R. D.</given-names></name>; <name><surname>Rodland</surname><given-names>K. D.</given-names></name>; <name><surname>Metz</surname><given-names>T. O.</given-names></name>; <name><surname>Pounds</surname><given-names>J. G.</given-names></name>; <name><surname>Waters</surname><given-names>K. M.</given-names></name><article-title>Review, evaluation, and discussion
of the challenges of missing value imputation for mass spectrometry-based
label-free global proteomics</article-title>. <source>J. Proteome Res.</source><year>2015</year>, <volume>14</volume> (<issue>5</issue>), <fpage>1993</fpage>–<lpage>2001</lpage>. <pub-id pub-id-type="doi">10.1021/pr501138h</pub-id>.<pub-id pub-id-type="pmid">25855118</pub-id></mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Wu</surname><given-names>J.</given-names></name>; <name><surname>Hao</surname><given-names>Z.</given-names></name>; <name><surname>Ma</surname><given-names>C.</given-names></name>; <name><surname>Li</surname><given-names>P.</given-names></name>; <name><surname>Dang</surname><given-names>L.</given-names></name>; <name><surname>Sun</surname><given-names>S.</given-names></name><article-title>Comparative
proteogenomics profiling of non-small and small lung carcinoma cell
lines using mass spectrometry</article-title>. <source>PeerJ</source><year>2020</year>, <volume>8</volume>, <elocation-id>e8779</elocation-id><pub-id pub-id-type="doi">10.7717/peerj.8779</pub-id>.<pub-id pub-id-type="pmid">32351780</pub-id></mixed-citation>
    </ref>
    <ref id="ref17">
      <mixed-citation publication-type="journal" id="cit17"><name><surname>Yi</surname><given-names>G.-z.</given-names></name>; <name><surname>Xiang</surname><given-names>W.</given-names></name>; <name><surname>Feng</surname><given-names>W.-y.</given-names></name>; <name><surname>Chen</surname><given-names>Z.-y.</given-names></name>; <name><surname>Li</surname><given-names>Y.-m.</given-names></name>; <name><surname>Deng</surname><given-names>S.-z.</given-names></name>; <name><surname>Guo</surname><given-names>M.-l.</given-names></name>; <name><surname>Zhao</surname><given-names>L.</given-names></name>; <name><surname>Sun</surname><given-names>X.-g.</given-names></name>; <name><surname>He</surname><given-names>M.-y.</given-names></name><article-title>Identification of
key candidate proteins and pathways associated
with Temozolomide resistance in glioblastoma based on subcellular
proteomics and bioinformatical analysis</article-title>. <source>BioMed
Res. Int.</source><year>2018</year>, <volume>2018</volume>, <fpage>5238760</fpage><pub-id pub-id-type="doi">10.1155/2018/5238760</pub-id>.<pub-id pub-id-type="pmid">29687002</pub-id></mixed-citation>
    </ref>
    <ref id="ref18">
      <mixed-citation publication-type="journal" id="cit18"><name><surname>Zhang</surname><given-names>B.</given-names></name>; <name><surname>Kall</surname><given-names>L.</given-names></name>; <name><surname>Zubarev</surname><given-names>R. A.</given-names></name><article-title>DeMix-Q:
quantification-centered
data processing workflow</article-title>. <source>Molecular &amp; Cellular
Proteomics</source><year>2016</year>, <volume>15</volume> (<issue>4</issue>), <fpage>1467</fpage>–<lpage>1478</lpage>. <pub-id pub-id-type="doi">10.1074/mcp.O115.055475</pub-id>.<pub-id pub-id-type="pmid">26729709</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
